ADAM metallopeptidase domain 21Genealiases: ADAM 21 · ADAM31
Q-omics provides the consensus-scored ADAM21 profile across patient tissues and cancer cell-line models. ADAM21 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ADAM21 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ADAM21 RNA expression shows 16,799 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where ADAM21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAM21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAM21 survival associations across molecular data types. ADAM21 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAM21 RNA expression–survival associations across cancer types. High ADAM21 expression shows unfavorable associations in MESO, CESC, STAD, COAD, LUAD and KICH. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ADAM21 RNA expression.
This table summarizes ADAM21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ADAM21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAM21 shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, LIHC, BRCA and LUAD. The KIRC box plot shows higher ADAM21 RNA expression in normal versus tumor tissue (log2 FC = −0.293, t-test p < 0.001).
This table shows molecular features associated with ADAM21 in patient tissues and cancer cell lines. In patient samples, ADAM21 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAM21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
